Apnimed’s IPO Bags $192M for What Could Become the First Oral Sleep Apnea DrugNews DeskAugust 2, 20260 Apnimed, a sleep disorders drug developer whose lead therapeutic candidate is under FDA review, raised $192 million in a stock…